Wegovy, step by step: dosing, side effects, and coverage realities

Wegovy is the brand name Novo Nordisk uses for semaglutide approved specifically for chronic weight management in adults and, more recently, adolescents 12 and older. The active ingredient is identical to Ozempic — both are semaglutide, both are injected subcutaneously once weekly, both work by activating the GLP-1 receptor.

The difference is the FDA-approved indication and the dose ceiling. Ozempic is approved for type 2 diabetes and tops out at 2.0 mg weekly. Wegovy is approved for chronic weight management in adults with a BMI ≥30, or ≥27 with a weight-related condition (such as hypertension, type 2 diabetes, or dyslipidemia), and titrates to a 2.4 mg weekly maintenance dose.

In practice, the difference matters for three reasons. First, the higher dose ceiling produces somewhat greater weight loss in trials. Second, insurance coverage rules treat the two products as distinct, and using Wegovy for weight loss is usually a cleaner reimbursement path than trying to get Ozempic covered off-label. Third, the marketing and patient education around Wegovy is built around weight management — the manufacturer materials, dosing reminders, and savings programs are all designed for that population.

Wegovy uses a fixed five-step titration. You start at 0.25 mg weekly for four weeks, then move to 0.5 mg for four weeks, then 1.0 mg for four weeks, then 1.7 mg for four weeks, and finally 2.4 mg as your maintenance dose. The full titration takes 16 weeks if everything goes smoothly.

The titration is not optional, and it is not a marketing flourish. Moving too fast is the single biggest driver of severe nausea and the single biggest reason patients stop the medication in the first eight weeks. The slow start is a tolerance-building protocol, not a teaser dose.

If you tolerate a step poorly, the standard guidance is to stay at the current dose for an additional four weeks before stepping up — sometimes longer. There is no medal for hitting 2.4 mg by week 16. The endpoint that matters is "the highest dose you can stay on consistently," and for some patients that is 1.0 mg or 1.7 mg, not 2.4 mg.

Once you reach maintenance, you stay there indefinitely as long as the medication is producing acceptable results and is well-tolerated. The maintenance phase is where most of the weight loss in the STEP trials occurred — the titration phase is mostly about getting you to the dose where the real effect happens.

STEP-1, published in the New England Journal of Medicine in 2021, was the pivotal trial that led to Wegovy’s approval for chronic weight management. It randomized 1,961 adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity, but without diabetes. Participants received Wegovy or placebo, both alongside lifestyle counseling, for 68 weeks.

The Wegovy arm achieved a mean weight reduction of 14.9% from baseline at week 68, compared with 2.4% in the placebo arm. About 86% of Wegovy participants lost at least 5% of body weight, more than half lost at least 15%, and roughly a third lost at least 20%. These numbers are dramatically better than what any prior anti-obesity medication had produced over a comparable period.

STEP-2 looked at adults with type 2 diabetes — a population in which weight loss tends to be harder. Wegovy produced about 9.6% mean weight loss over 68 weeks, still well above placebo and historical comparators. STEP-3 added an intensive behavioral intervention to Wegovy and produced even larger losses (around 16%). STEP-4 looked at the question of what happens when you stop: patients who switched from Wegovy to placebo at week 20 regained most of the lost weight by week 68. Patients who continued Wegovy continued losing.

The larger STEP-5 trial, with two-year follow-up, showed weight loss being sustained through 104 weeks. The pattern across all the STEP trials is consistent: the medication produces large, sustained weight loss while taken, and discontinuation produces regain.

The side effects of Wegovy are dominated by gastrointestinal symptoms, especially in the first week or two after each dose increase. Nausea is the most common, affecting roughly 40–45% of patients at some point in trials. Constipation, diarrhea, vomiting, abdominal discomfort, and reflux are also common. Most events are mild to moderate and fade within several days.

Practical management is mostly behavioral: smaller, more frequent meals; protein and fiber up front; lower-fat foods during the worst stretches; hydration; ginger or B6 for nausea; gentle laxatives or fiber for constipation. Eating slowly and stopping when you feel full (which on Wegovy is much sooner than your old baseline) makes a big difference.

Less common but worth knowing: fatigue, headache, dizziness, taste changes, and a temporary loss of interest in foods you used to enjoy. Some patients find that alcohol affects them more strongly than before.

Serious adverse events are uncommon but include pancreatitis, gallbladder disease (gallstones can be triggered by rapid weight loss in general, not just by GLP-1s), and rare bowel obstruction. The class warning for medullary thyroid carcinoma applies — Wegovy is contraindicated in patients with a personal or family history of MTC or MEN2. Severe, persistent abdominal pain is always a reason to stop dosing and get evaluated.

Insurance coverage for Wegovy in 2026 is improving but still inconsistent. Many commercial plans cover it under their obesity-treatment benefit, but most require a prior authorization that documents your BMI, your weight-related conditions, prior weight-loss attempts, and a treatment plan from a clinician. The PA process can take days to weeks and may need to be repeated annually.

Some plans exclude obesity medications entirely. Some cover Wegovy for cardiovascular risk reduction (which the FDA approved as a separate indication for Wegovy in 2024) but not for weight loss alone. Some cover it only after a documented trial of older, cheaper medications. The plan-by-plan variation is enormous, and the only way to know what your plan does is to call.

Medicare Part D historically did not cover GLP-1s for weight loss because of a long-standing statutory carve-out for obesity drugs. As of 2024–2025, the cardiovascular indication for Wegovy opened a partial path to Medicare coverage for patients who also have established cardiovascular disease. Medicaid coverage varies by state.

A good telehealth or weight-management clinic will know which plans cover what in your state and will handle the prior authorization paperwork. If coverage is not available, the cash list price for Wegovy in 2026 is roughly $1,300 per month, and the manufacturer offers a savings card that can lower the cost substantially for commercially insured patients without coverage. There are also patient-assistance programs for uninsured patients with financial need.

Once you reach 2.4 mg and have settled into the maintenance phase, the most important things to track are weight, side effects, and quality of life. The goal is not maximum loss — it is sustainable loss with side effects you can live with.

If you are losing steadily and feel reasonably well, no changes are needed. Many patients continue at 2.4 mg for a year or more before plateauing.

If you have hit a comfortable weight and want to step down, some clinicians experiment with maintenance at 1.7 mg or even 1.0 mg. There is less trial data on this approach than on staying at full dose, but case experience suggests that some patients can hold loss at lower doses with fewer side effects. This is a conversation to have with the clinician who knows your full picture.

If side effects become unmanageable, the right move is usually to step down a dose for several weeks and try again — not to push through. Quitting the medication entirely is a much larger setback than spending a few extra months at a lower dose.

If weight loss has stalled for three months despite full adherence, the conversation is about whether to switch to a different agent (tirzepatide is a common next step), add a second agent, or accept the current weight as a new setpoint and shift the goal to maintenance.

STEP-4 is the trial that gets cited most often on this topic, and the headline is direct: patients who discontinued Wegovy after 20 weeks regained roughly two-thirds of the lost weight by week 68. Patients who continued Wegovy continued losing. The biological reasons are not mysterious — appetite normalizes, food noise returns, metabolic adaptation gradually reverses.

That makes "should I come off?" a real conversation rather than a default. For most patients, the right framing is the same as for any chronic medication: stay on it as long as it is producing benefit and is tolerated.

For patients who do choose to discontinue — because of side effects, cost, pregnancy planning, or personal preference — the smart approach is to do so with a deliberate maintenance plan. That means structured eating, resistance training, sleep, and ongoing weigh-ins, and it means knowing what your re-start criteria would be if regain becomes significant.

A common pattern is gradual taper — moving from 2.4 mg back down through 1.7, 1.0, 0.5, and 0.25 mg over several months — rather than abrupt discontinuation. The data on tapering versus stopping cold is limited, but a slower transition is generally easier on the body and on the rebound appetite.

The single most underestimated part of being on Wegovy is the lifestyle work that determines whether the on-medication weight loss translates into long-term metabolic health. The medication makes the changes possible by quieting appetite and food noise, but it does not do the work for you. The patients who get the best long-term outcomes treat the on-medication phase as a window to build the structural habits that will outlast the prescription.

Protein intake. During rapid weight loss, the body is more likely to break down lean tissue for energy unless protein intake is consistently high. The widely cited target for active weight loss is 1.2 to 1.6 grams of protein per kilogram of body weight per day, which for many adults means 100 to 150 grams per day. This is more than most people eat by default, and on Wegovy it requires intentional planning because appetite is suppressed. Protein-forward meals (eat the protein first, then the rest) are the practical move.

Resistance training. GLP-1 medications do not preferentially burn fat versus muscle — they create a calorie deficit, and calorie deficits without resistance training cause some loss of both. Three to four sessions per week of compound resistance exercise (squats, deadlifts, presses, rows, in some form scaled to your level) is the most effective intervention for preserving lean mass. The exact program matters less than the consistency.

Sleep. Insufficient sleep raises ghrelin (hunger hormone) and lowers leptin (satiety hormone), which fights against the appetite suppression Wegovy provides. Patients who sleep poorly often plateau earlier than patients with similar adherence and better sleep. Seven to nine hours per night is the target most sleep researchers recommend; meeting it consistently is one of the higher-leverage interventions you can layer on top of the medication.

Hydration and fiber. Wegovy slows gastric emptying, and dehydration plus low fiber intake is the recipe for the constipation that troubles many patients. Adequate water and 25-35 grams of fiber per day from food sources (vegetables, fruit, legumes, whole grains) handles most of the constipation issue without supplementation.

Patients who do these four things consistently are dramatically more likely to maintain their loss when they eventually come off Wegovy — or to maintain it on a lower maintenance dose. Patients who let the medication do all the work and skip the lifestyle layer regain quickly when the medication stops. The framing that has helped many patients is to treat Wegovy as a temporary helper that buys you the headspace to build the long-term system, not a replacement for the system.